Description

Simple

Clinical

Overview

Pharmacology

Indication

Information currently not available.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Farnesyl diphosphate
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
Abexinostat
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Abexinostat.
Acebutolol
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Acebutolol.
Aceprometazine
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Aceprometazine.
Acetyldigoxin
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Acetyldigoxin.
Acrivastine
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Acrivastine.
Adenosine
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Adenosine.
Ajmaline
The risk or severity of QTc prolongation can be increased when Ajmaline is combined with Farnesyl diphosphate.
Alfuzosin
The risk or severity of QTc prolongation can be increased when Alfuzosin is combined with Farnesyl diphosphate.
Alimemazine
The risk or severity of QTc prolongation can be increased when Alimemazine is combined with Farnesyl diphosphate.
Amantadine
The risk or severity of QTc prolongation can be increased when Amantadine is combined with Farnesyl diphosphate.
Amifampridine
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Amifampridine.
Amiodarone
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Amiodarone.
Amisulpride
The risk or severity of QTc prolongation can be increased when Amisulpride is combined with Farnesyl diphosphate.
Amitriptyline
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Amitriptyline.
Amodiaquine
The risk or severity of QTc prolongation can be increased when Amodiaquine is combined with Farnesyl diphosphate.
Amoxapine
The risk or severity of QTc prolongation can be increased when Amoxapine is combined with Farnesyl diphosphate.
Anagrelide
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Anagrelide.
Anisodamine
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Anisodamine.
Antazoline
The risk or severity of QTc prolongation can be increased when Farnesyl diphosphate is combined with Antazoline.
Apomorphine
The risk or severity of QTc prolongation can be increased when Apomorphine is combined with Farnesyl diphosphate.